Abstract:Introduction: The cooperative group experience of thoracic sterotactic body radiation therapy (SBRT) in medically inoperable patients with early stage non-small cell lung cancer (NSCLC) historically utilized corticosteroid premedication. Patterns of care have been mixed as to whether premedication adds benefit in terms of improved lung toxicity and treatment tolerance. Methods: Patients treated for NSCLC from 2014 to 2017 with definitive thoracic SBRT (BED10≥100) at a single institution, in a prospectively collected database were evaluated. Pretreatment clinicopathologic characteristics, including Eastern Cooperative Oncology Group (ECOG) performance status, PFT parameters of FEV1, and diffusing capacity for carbon monoxide (DLCO) were collected. Treatment and dosimetric characteristics were collected, and patients were scored as to whether dexamethasone was prescribed and utilized with each fraction. Toxicity was graded on multiple domains including lung as during and 30 days after completion of treatment using Common Terminology Criteria for Adverse Events Version 4. Univariate analysis was performed with Fisher's exact test for categorical variables and two-tailed Student's t-test for continuous variables. Multivariate analysis was performed with Cox proportional hazards model to adjust for age, pretreatment DLCO, ECOG, tumor size, central versus peripheral location, and biological effective dose. Results: A total of 86 patients treated with thoracic SBRT with 54-60 Gy in 3-8 fractions met inclusion criteria, with the majority (70%) receiving 5 fractions. Of these patients, 45 (52%) received 4 mg dexamethasone premedication prior to each fraction of SBRT and 41 (48%) were treated without dexamethasone premedication. Overall acute lung toxicity was low in both groups. Between the two groups of patients, 5/45 (11%) developed grade 2 or higher lung toxicity including hospital admission in the dexamethasone premedication arm vs. 2/41 (5%) without premedication (p = 0.4370, Fisher's exact test). Freedom from acute SBRT lung toxicity was no different between dexamethasone premedication arm and no premedication (Log rank, p = 0.45). On multivariate Cox proportional hazard modeling adjusting for age, ECOG, tumor size, central vs. peripheral location, pretreatment DLCO, and BED, there was no difference in freedom from acute lung toxicity without dexamethasone premedication (HR: 0.305; 95% CI: 0.033, 2.792; p = 0.293). Conclusions: In this retrospective analysis, pretreatment steroid prophylaxis with dexamethasone confers a similar acute toxicity profile and no added clinical benefit to treatment without pretreatment steroid prophylaxis.

Impact of Prophylactic Dexamethasone on the Efficacy of Immune Checkpoint Inhibitors Plus Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer

Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy

Effect of Pretreatment with Dexamethasone on the Efficacy and Immune-Related Adverse Events of Immunotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer: a Network Meta-Analysis of Randomized Control Trials.

Influence of Dexamethasone Premedication on Acute Lung Toxicity in Lung SBRT

Impact of baseline steroids on the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma

Abstract B098: Impact of dexamethasone on chemotherapy response in ovarian cancer

Analysis of the Association Between Prior Chemotherapy Regimens and Outcomes of Subsequent Anti-Pd-(l)1 Monotherapy in Advanced Non-Small Cell Lung Cancer.

Efficacy and Safety of PD-L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.

Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.

Abstract 5058: Impact of dexamethasone on chemotherapy response in ovarian cancer

Impact of dexamethasone on transplant-related mortality in pediatric patients: a multi-site, propensity score–weighted, retrospective assessment

Impact of Clinicopathological Features on the Efficacy of Immune Checkpoint Inhibitors Plus Conventional Treatment in Patients with Advanced Lung Cancer

[Effect of Dexamethasone on Cisplatin Induced Apoptosis in Primary Cells from Resected Specimens with Chinese Human Lung Adenocarcinoma Ex Vivo].

Dexamethasone Pretreatment Impairs the Thymidylate Synthase Inhibition Mediated Flare in Thymidine Salvage Pathway Activity in Non-Small Cell Lung Cancer

Glucocorticoid Reduces Pemetrexed Sensitivity by Mediating Senescence-Associated Secretory Phenotype in Bcl-2 Dependent Manner in Non-Small-Cell Lung Cancer

Comparative study of dexamethasone premedication regimens with docetaxel chemotherapy in early HER-2 positive breast cancer: A safety net hospital experience

Association of Glucocorticoid Receptor Expression with the Treatment Outcome of Pemetrexed-Based Chemotherapy in NSCLC Patients.

High Pretreatment DHEA Is Associated with Inferior Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer

Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine

Dexamethasone Alleviates Pemetrexed-Induced Senescence in Non-Small-Cell Lung Cancer.

Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study